The GOBLET study aims to evaluate the efficacy of pelareorep in combination with atezolizumab and chemotherapy in patients with advanced pancreatic cancer. Preliminary biomarker data suggest that patients receiving this combination therapy may experience a shift towards a more immune-active tumor state, which could lead to improved clinical outcomes. The study's findings are particularly significant given the high unmet medical need in pancreatic cancer, where traditional therapies have limited effectiveness.
In addition, the AWARE-1 study is exploring the effects of pelareorep in early-stage breast cancer, with a focus on its ability to drive coordinated anti-tumor immune responses. The formation of tertiary lymphoid structures (TLS) has been observed in patients treated with pelareorep, which may enhance the effectiveness of immunotherapy in previously resistant tumors.
Jared Kelly, CEO of Oncolytics, emphasized the importance of these findings, stating, "The coordinated immune activation and TLS formation we are observing support pelareorep as a foundational backbone for combination therapy across multiple tumor types, including RAS-driven cancers. As we advance registrational programs in gastrointestinal cancers, we believe pelareorep will enhance immunotherapy activity and potentially help patients who did not respond initially."
The acceptance of these abstracts at AACR 2026 is expected to generate significant interest among oncologists and researchers, potentially leading to increased visibility and support for Oncolytics' clinical programs. The company is actively pursuing strategic partnerships to accelerate the development of pelareorep and maximize its commercial impact in the oncology market.
